Alex Goldberg

MannKind Corp. (NASDAQ:MNKD) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 07/18/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding MannKind Corp. (NASDAQ:MNKD) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

MannKind Corp. (NASDAQ:MNKD) a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States closed down in its previous session (-0.41%) on 3,094,321 shares traded. MannKind Corp. (NASDAQ:MNKD) is currently down (-11.04%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about MannKind Corp. (NASDAQ:MNKD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a biopharmaceutical company that focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders closed down in its previous session (-0.45%) on 1,670,852 shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is currently down (-3.9%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com